{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-043771","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2026-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.108559+00:00","generated_at":"2026-05-16T03:41:04.253400+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis","bullets":["Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.","Frequentist analysis showed p<0.01 at weeks 4, 8, 12; 33% placebo-adjusted EASI reduction at week 12.","23% of EVO301 patients achieved vIGA-AD 0/1 at week 12 vs 0% placebo.","EVO301 well tolerated; no related serious/severe AEs or treatment discontinuations.","Company plans Phase 2b dose-ranging trial with subcutaneous formulation; evaluating ulcerative colitis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-043771","json":"https://secwatch.observer/filing/0001193125-26-043771.json","markdown":"https://secwatch.observer/filing/0001193125-26-043771.md","text":"https://secwatch.observer/filing/0001193125-26-043771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/0001193125-26-043771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-20260210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:41:04.253400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}